Signaling antibodies in cancer therapy
- 26 October 1999
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 11 (5), 541-547
- https://doi.org/10.1016/s0952-7915(99)00010-2
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategyEuropean Journal Of Cancer, 1999
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- Human antibodies by designNature Biotechnology, 1998
- POSITIVE VERSUS NEGATIVE SIGNALING BY LYMPHOCYTE ANTIGEN RECEPTORSAnnual Review of Immunology, 1998
- The association between CD20 and Src-family Tyrosine kinases requires an additional factorMolecular Immunology, 1998
- The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinaseOncogene, 1998
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Prevention of breast tumour development in vivo by downregulation of the p185neureceptorNature Medicine, 1995
- IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.Proceedings of the National Academy of Sciences, 1982